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Abstract
Background: The rate of progression of the disease depends on various factors and the tumor microenvironment
takes not the last place among them. One part of researchers argues that the presence of tumor-infiltrating leukocytes
serves as a favorable marker of the disease. There exists a completely different point of view on the matter.
The investigation of the effects of the inflammatory infiltration on the course of breast cancer process.
Methods: We found a pronounced inflammatory infiltration in the tumor microenvironment in 24 cases. Nineteen
cases of IDC without inflammatory infiltration were used as a control group. Immunohistochemical reaction showed
expression of ERα, PR, HER2/neu, E-cadherin, Hsp90α, Bcl-2, CD3, CD79α, S100 and Myeloperoxidase receptors.
Mathematical calculations were done using Microsoft Excel 2010 with 12.0.5 Attestat option.
Results: We have determined five variants of immune microenvironment: interstitial, trabecular, nodular, diffuse and
mixed. We have established a direct correlation between the expression of ERα and PR and indirect correlation between
the receptors of steroid hormones and HER2/neo in both groups of breast cancer. HER2/neo positive tumors in 100% of
cases were accompanied by the presence of heat shock proteins. There was a combination of Bcl-2 presence with the
steroid receptors expression in 90 % of cases. There was found the indirect correlation between the presence
of B lymphocytes and expression of steroid receptors.
Conclusions: The presence of B lymphocytes in an inflammatory infiltrate leads to the disappearance of estrogen
receptors and progesterone receptors. It provokes the accumulation of Hsp90 in a cell. It contributes to the stabilization
of HER2/neu receptors and most proteins that promote tumor progression.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1362330168161694
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Background
The rate of progression of breast cancer depends on
various factors. The histological type of tumor, its reasons,
the woman’s age, the hormonal condition, the tumor
microenvironment, the status of the receptors and genetic
material, etc. were described as the prognostic factors of
breast cancer [1].
There are two different forms of estrogen receptor (ER),
usually referred to as α and β, each encoded by a separate
gene (ESR1 and ESR2, respectively). ESR1 is localized on
the sixth chromosome, and ESR2 - on the fourteenth
chromosome [2]. The connection of the hormone (17β-
estradiol) with receptors causes dissociation of the com-
plex with receptor protein hsp90, which impedes the
transition of the receptor in the active conformational
state. Further, as a heterodimer receptor it interacts with
the estrogen response element (ERE), increasing the ex-
pression of the necessary genes [3]. The gene that encodes
the progesterone receptor (PR) is located on the eleventh
chromosome. The number of PR increases with the rising
amount of estradiol and ER because they are synthesized
after ER [4]. In contrast to these favorable prognostic indi-
cators, the presence of human epidermal growth factor
receptor 2 (HER2/neu) is a factor of tumor aggression.
ERBB2 (coding gene HER2/neu), known as proto-
oncogene, is located on a long arm of human seventeenth
chromosome [5, 6].
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The self-regulation tumorous process and participation
of antitumor immunity in it are acute in many scientific
studies. From this perspective the tumor microenviron-
ment occupies a key position. One part of researchers
argues that the presence of tumor-infiltrating leukocytes
serves as a favorable marker of the disease [7]. The
studies of the relationship between immune response
and prevalence of breast cancer have shown that with
the decrease of leukocyte infiltration around the tumor
cells the frequency of regional lymph nodes lesion is
increased [8]. On the one hand the immune micro-
environment restricts prevalence of the tumor, on the
other hand manifests its cytotoxic effect against the
phenotypic-foreign breast cancer cells. There exists a
completely different point of view on the matter [9].
It has been shown that the immune microenviron-
ment determines the proliferative activity of the
tumor, metastasis and cell migration. This process is
carried out by the ability of cells to perceive signaling
molecules such as pro-inflammatory cytokines, selec-
tins, chemokines which are secreted by inflammatory
cells as well as secrete them. But as it turned out the
prognosis of breast cancer depends more on qualita-
tive composition of the infiltration [10].
The questions about the influence of the inflammatory
response on the expression of the receptors have been
discussed in a great deal of studies repeatedly [11].
Nuclear factor (NF-kB) was described as one of the inhi-
biting factors for ER [12]. It is activated by a variety of
stimuli, including cytokines (interleukin 1 - IL-1) and
stress factors (such as reactive forms of oxygen). In the
presence of IL-1, NF-kB becomes active. It is translo-
cated into the nucleus for activation the transcription of
the controlled genes. NF-κB can inhibit ER in different
ways activating inhibitors and inhibiting activators of
ESR1 and ESR2 transcription [13–15].
One important mechanism of cell survival is the
activation of the transcription different anti-apoptotic
proteins of the bcl-2 family by NF-kB signaling cascade
[16, 17]. One of pro-survival proteins Bcl-2 family bcl-2
inhibits caspases due to the prevention of exiting cyto-
chrome C from mitochondria and/or due to the binding
factor APAF1 which activates apoptosis [18]. There is
information that transcription of the gene Bcl-2 is acti-
vated by the signals received from the ER [19].
Heat shock protein 90 (hsp90, chaperone 90) is one
of regulatory factors which controls activity of HER2/
neu receptors [20]. It has been suggested that hsp90
modulates the effects of oncogenic HER2/neu, repre-
senting a potential mechanism of breast cancer resist-
ance to HER2/neu directed drugs [21]. They are
involved in maintaining the integrity of mitochondrial
activating bcl-2, promoting the invasion step of
metastasis and regulating the activity of factors Akt,
NF-kB and JKN [22, 23]. Many investigations have
shown the cross-resistance phenomenon in which
some damaging agents (oxidase stress, heavy metal
ions, inflammatory process) cause induction of hsp90
synthesis and adaptive response to other factors [24].
Analyzing the above it can be concluded that the
inflammatory cells of the tumor microenvironment
are directly involved in cell activity. The mechanism
of combined effect immune cells on the expression of
vitally important receptor of breast cancer cells re-
mains unclear.
The objectives of this paper are as follows: the investi-
gation of the effects of the inflammatory infiltration on
the course of malignant process by determining qualita-
tive composition of tumor microenvironment and
studying the expression of the prognostic-important
receptors in the breast cancer cells.
Methods
We selected 43 samples of breast cancer tissue. The
diagnosis of invasive ductal carcinoma (IDC) with vary-
ing degrees of malignancy (by Scarff-Bloom-Richardson)
was found after the standard hematoxylin eosin
staining of prepared slices. We found a pronounced
inflammatory infiltration in the tumor microenviron-
ment in 24 cases. Nineteen cases of IDC without in-
flammatory infiltration were used as a control group.
The material for the immunohistochemical reaction
was fixed in 10 % neutral formalin for 24 h, after
that paraffin blocks were made of it. Then sections
with the thickness of 3–4 mm were made and they
were subjected to the standard process of dehydra-
tion in xylol and alcohols of rising concentration.
Immunohistochemical reaction consisted of 2 stages.
During the first stage incubation with primary rabbit
antibodies in different dilutions took place (Table 1).
We used the following antibodies for determining the
qualitative composition of infiltration: CD3 was used
for the determination of T lymphocytes, CD79α – for
B lymphocytes, the searching of the antigen present-
ing cells was performed using S100 antibody, myelo-
peroxidase (MPO) being detected in myeloid cells of
both neutrophilic and eosinophilic types. We have
performed immunohistochemical reaction with E-
cadherin for the purpose of the differential diagnosis
between invasive lobular carcinoma and high degree
malignant IDC. The positive reaction took place only
in IDC.
The incubation with secondary antibodies (UltraVision
ONE HRP Polymer) took place during the second
stage. We visualized the cell structural components
using diaminobenzidine, which painted them in a
brown color.
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We calculated the share of different forms of immune
cells and their ratio analyzing the histological and immu-
nohistochemical study. The study was conducted in 10
fields of view at 400× magnification.
Mathematical calculations were done using Microsoft
Excel 2010 with 12.0.5 Attestat option. We have found
such indicators as chi-squared Pearson’s test, Student’s
T-criterion, Pearson’s correlation coefficient (with statis-
tical significance p < 0.05).
Results
At histological examination of cases with inflammatory
infiltration we have found that immune cells are located
in different variations around the tumor cells. Among
the immune cells, we found that most cells had a
rounded shape with a rounded nucleus and a small
amount of cytoplasm of approximately 6mkm which
were identified as lymphocytes. Considering histological
features we were unable separate them on T or B
lymphocyte groups. Among them we found the histio-
cytes which were characterized by the presence of vari-
ous (round, elongated or irregular) forms, heterogeneous
spotted basophilic cytoplasm (due to the presence of
lysosomes) of approximately 13mkm. There were also
found scattered segmented granulocytes various forms
with contained intracellular granularity. We have deter-
mined five variants of immune microenvironment:
1. Interstitial - the leukocytes are located around the
tumor as single scattered cells.
2. Trabecular – the immune cells form the layers or
trabeculae.
3. Focal (nodular) – the leukocytes accumulate in
focuses, sometimes with the formation of pseudo-
follicles.
4. Diffuse - the immune cells occupy almost all the
intercellular space giving the impression of metastasis
in lymph nodes (Fig. 1).
5. Mixed – a combination of different forms of
inflammatory infiltration.
In the stroma of the control group tissue the immune
cells were also presented, because they are a part of the
fibrous tissue of any organs, including the mammary
gland. But they are located singly and very rare.
A clear relationship between the degree of malignancy
of IDC and the type of inflammatory infiltrate has not
been detected (p > 0.05). It was observed a tendency of
infiltration increase in the case of the growth of poly-
morphism “cancerous” cells. This suggests a more pro-
nounced reaction of macroorganism with the increase of
cell’s anaplasia.
Immunohistochemical analysis has revealed different
variants of ERα, PR and HER2/neu expression (Table 2).
We have established a direct correlation between the
expression of ERα and PR (r = +0.78, p < 0.05) and
indirect correlation between the receptors of steroid
hormones and HER2/neo (r = −0.73, p < 0.05) in both
groups of breast cancer. The combination of the steroid
receptors absence and presence of HER2/neo with the
presence of inflammatory infiltration in the tumor
microenvironment have been established in our study.
In most cases, it did not depend on the type of inflam-
matory infiltration.
Studying the expression of bcl-2 in cancer cells the
investigation has showed that 40 % of tumors were bcl-2
positive. There was a combination of their presence with
the steroid receptors expression in 90 % of cases. It was
found that hsp90α in tumor cells were characterized by
cytoplasmic and nuclear localization. Nearly 80 % cases
of breast cancer were positive for Hsp90α expression,
indicating their participation in tumor development. The
correlation was established between the level of hsp90α
expression by tumor epitheliocytes and the leukocyte
infiltration in stromal tissue (p < 0.05). HER2/neo posi-
tive tumors in 100 % of cases were accompanied by the
presence of heat shock proteins.
While studying the qualitative composition of the
inflammatory infiltration it has been found that the
immune cells were white blood cells of different nature.
The lymphocytes dominated among them. We have
established that the lymphocytes of T (CD3) and B
(CD79α) cell lines were present among them. Such
forms of the leukocytes as monocytes (S100) and various
forms of granulocytes (MPO) were also present in the
immune microenvironment of the tumor. B lymphocytes
were present in 20 to 60 % of the total number of leuko-
cytes. We found that the number of T lymphocytes has
been approximately 25–70 % of the total number of
leukocytes. The total number of T and B lymphocytes
was 85–90 %. The number of granulocytes was 1–7 %,
macrophages were up 15 %. The antigen presenting
Table 1 Antibody for immunohistochemical reaction
Antibody Host Clone Dilution Cellular localization
ERα Rabbit SP1 1:200 Nuclear
PR Rabbit YR85 1:150 Nuclear
HER2/neu Rabbit SP3 1:100 Membrane
E-cadherin Rabbit 67A4 1:100 Membrane
Hsp90α Rabbit Polyclonal 1:200 Cytoplasmic
and nuclear
Bcl-2 Mouse 100/D5 1:100 Cytoplasmic
CD3 Rabbit SP7 1:150 Membrane
CD79 α Rabbit SP18 1:200 Membrane
S100 Mouse 4C4.9 1:150 Cytoplasmic
Myeloperoxidase Rabbit Polyclonal 1:100 Cytoplasmic
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monocytes were observed in most cases with B lympho-
cytes. An important aspect of the research is the study
of the ratio between different types of leukocytes. Our
study showed that in the case of steroid-negative breast
cancer the ratio В-lymphocytes:T-lymphocytes:granulo-
cytes:antigen presenting monocytes was an average as
follows 6:2,5:0,5:1. It means that the number of B
lymphocytes was more than 60 % and T lymphocytes
were near 25 %. There was found the indirect correlation
between the presence of B lymphocytes and expression
of steroid receptors (p < 0.05). The ratio of imunocytes
in steroid-positive breast cancer was an average as
follows 2:7:0,5:0,5.
Commending the above, we can state the fact that,
depending on qualitative composition of the immune
microenvironment the different expression of the
prognostic markers are observed in breast cancer
cells (Fig. 2).
Concerning PR, its quantity directly depends on the
amount of ER. This indicates their simultaneous
synthesis and dependence of PR from the presence and
quantity of ER [4].
Discussion
The progression of breast cancer depends on many
factors, including the tumor microenvironment. The
surrounding inflammatory infiltration in the list of prog-
nostic factors is not the last place. We cannot exclude
its effect on the expression of receptors. This is clearly
seen in these types of breast cancer, such as medullary
and inflammatory carcinoma, which are always accom-
panied by pronounced inflammatory infiltration in the
microenvironment. They have the negative status of the
receptors for steroid hormones in most cases.
In our opinion, there are several reasons for the
appearance of immunocytes among the tumor cells.
Therefore as a tumor is an immunologically foreign
tissue, the macroorganism is constantly struggling with
it. This is only possible on condition that different forms
of leukocytes are involved in this process. On the other
Fig. 1 The variants of immune microenvironment: a – interstitial, b – trabecular, c – focal, d – diffuse. I – the tumor tissue; II - the immune cells.
The hematoxylin eosin staining. Magnification × 100
Romaniuk and Lуndіn Diagnostic Pathology  (2015) 10:79 Page 4 of 8
hand, the impact of exogenous factors that stimulate
inflammation may also influence the course of carcino-
genesis. For example an increased penetration of heavy
metal salts into the body leads to their accumulation in
tumor tissue. The activation of the immune system
occurs by the stimulation of oxidase stress and increase
of tissue calcification in which they take part.
Undoubtedly the inflammatory infiltration influences
up the receptor expression, but as can be seen from our
results it is not dependent on the type of infiltration. It
depends on the qualitative composition of cellular
microenvironment. The sequence of events is as follows.
The macroorganism recognizing the tumor as a
foreign substance starts primarily the cellular immun-
ity. The more tumor cells are foreign the more this
reaction is expressed. It consists of the activation of
the antigen-specific cytotoxic T (CD3) lymphocytes by
immunocompetent macrophages (S100), which can
cause apoptosis of tumor cells. After that the apop-
totic corpuscles are phagocytized by the segmented
leukocytes (MPO). This process does not influence on
the expression of ERα and PR.
We saw quite a different picture in the case of the
involvement of the humoral immunity in the struggle
against cancer. The antigen presenting cells recognize
antigen presented by tumor cells and present it through
IL-1 to Th2. Th2 through IL-3 activate B lymphocytes.
The secretion of IL-1 is accompanied by the transition
of NF-kB in the active form. NF-kB stimulates protein
kinase B, also known as Akt, which inhibits the activity
of forkhead box O3 (FOXO3A) [13]. NF-kB influences
on ER expression through stimulation of EZH2 (enhan-
cer of zeste homolog 2) activity [14] and the activation
of BLIMP-1 (PR domain zinc finger protein 1) [15]. The
reduction of the number of FOXO3A, increasing of the
number of EZH2, Akt and BLIMP-1 inhibit ER
transcription. As a consequence the expression of intra-
nuclear receptors for estrogen is reduced. Based on this,
we explain the absence of ER in our study when В lym-
phocytes predominate in the tumor microenvironment.
A correlation between the level of Hsp90α expression
and the leukocyte infiltration in breast cancer stromal
tissue shows the influence of the immune microenviron-
ment on the presence of the heat shock proteins. His
constant presence with HER2/neu positive breast cancer
confirms his participation in tumor progression. Hsp90α
stabilizes HER2/neu and modulates their effect [20]. It
stimulates the resistance of breast cancer to HER2/neu
directed drugs [21]. This may explain the fact why
ERBB2 gene amplification is not always accompanied by
the expression of HER2/neu, which may be linked to the
lack of Hsp90α. This chaperone effects on ER and PR,
on the one hand stabilizing their structure, on the other
hand regulating activity of Akt and NF-kB [3, 22]. Hsp90
promotes the activation of anti-apoptotic protein kinases
(bcl-2) and blocks APAF-1, the protein of internal apop-
totic way, thereby bolstering the development of cell re-
sistance to their programmed death [25]. Based on this,
increasing the number of Hsp90 in the conditions of
oxidase stress and inflammation leads to the increase of
tumor cell resistance and assists in the expression of
prognostically unfavorable receptors. Hsp90 worsens the
prognosis of breast cancer because it also modulates the
synthesis of such proteins as p53, angiogenic factor HIF-
1a, VEGF and others, which are aggressive factors in the
cancer process [26].
Previous studies have shown that Bcl-2 was expressed
almost exclusively in ER+ diseases (about 85 %) because
BCL2 is an estrogen-responsive gene [27]. The same
results have been obtained in our studies in estrogen-
positive breast cancer cases. It is believed that the
presence of Bcl-2 receptors is a favorable prognostic
factor [28]. While Bcl-2 has emerged as an important
prognostic marker in breast cancer, its precise role as a
predictive marker or therapeutic target is not known
[29]. We believe that the presence of Bcl-2 protein is not
an indicator of favorable course. This is one of the ways
to improve the implementation of proliferative potential
of cells through the ER. Inasmuch as a function of
estrogen is the amplification of cell division, it can
be implemented either through transcription of estrogen-
dependent genes that are responsible for the separation or
through activation of transcription estrogen-dependent
genes that block apoptosis such as BCL-2. In our
opinion the presence of Bcl-2 indicates a more
aggressive course of breast cancer. Formerly it was
considered as a prognostically favorable factor due to
the presence in most cases the receptors of steroid






Luminal A ER+ 3 13
PR+/−
HER2/neu−
Luminal B ER+ 1 1
PR+/−
HER2/neu+
Triple negative ER− 15 2
PR−
HER2/neu+
HER2 type ER− 5 3
PR−
HER2/neu−
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hormones that are prognostically favorable markers of
breast cancer.
Moreover the research has shown that therapeutic
effect is enhanced in concurrent usage of the estrogen
receptor inhibitors and BH3 mimetics, which have
been developed to counteract antiapoptotic proteins
such as Bcl-2 and Bcl-2-related proteins Bcl-XL and
Bcl-W [30]. There is also NF-кB-dependent way of
activation synthesis anti-apoptotic members of the
Bcl-2 family (Bcl-2, Bcl-XL and BFL1) [17, 31]. And
again we must remember about inflammation, IL-1
and their effects on NF-kB synthesis, through which
they support resistance of cancer cells in the struggle
for survival. That is why we observed isolated cases
Bcl-2 positive breast cancer (weakly intense reaction)
in cases of ER absence.
The general sequence of influence inflammation on
the receptors of breast cancer cells is shown in
Scheme 1.
Analyzing obtained data we can assert that immune
microenvironment plays one of key roles in the progres-
sion of malignant process. This may explain those cases
of breast cancer, when the cells with different phenotype
of the receptor status can be found in one section. On
the one hand, this means that the cells lose their ability
to perceive signals from the macroorganism, on the
Fig. 2 The immunohistochemical study of breast cancer tissue. 1 – ERα, 2 – PR, 3 - HER2/neu, 4 - Hsp90α, 5 - Bcl-2, 6 – CD3, 7 – CD79α,
8 – MPO, 9 - S100
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other hand they adapt to new environment becoming
more resistant. A similar situation occurs in metastases
in the lymph nodes, where tumor cells are surrounded
by B lymphocytes.
Immune system cells influence upon the course of
cancer, but we haven’t found yet whether positive or
negative. We consider that the immunocytes remove the
influence of steroid hormones by blocking estrogen
receptors as a factor of tumor initiation in the mammary
gland. But in the future progress it begins to contribute
to carcinogenesis progression.
Conclusions
The immune microenvironment through the activation
of intracellular mediators blocks ERS genes transcrip-
tion. This circumstance is possible due to the presence
of B lymphocytes in an inflammatory infiltrate. It leads
to the disappearance of estrogen receptors, and as a
result to the disappearance of progesterone receptors.
The inflammation provokes the accumulation of Hsp90
in a cell. It contributes to the stabilization of HER2/neu
receptors and most proteins that promote tumor
progression. The lack of estrogen receptors is a factor of
locking estrogen-dependent gene BCL-2 transcription
and as a consequence to the decrease of Bcl-2. All of the
above stimulates the breast cancer progression by pro-
viding tumor more malignant opportunities.
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